A recent report published by Infinium Global Research on the thymus cancer market provides an in-depth analysis of segments and sub-segments in the global as well as regional thymus cancer market. The study also highlights the impact of drivers, restraints, and macro indicators on the global and regional thymus cancer market over the short term as well as long term. The report is a comprehensive presentation of trends, forecast and dollar values of the global thymus cancer market. According to the report, the global thymus cancer market is projected to grow at a CAGR of 5.4% over the forecast period of 2019-2025.

Market Insight

Thymus cancers are rare tumors occurred in a small organ located behind the breastbone in front of the chest. The thymus is of vital importance to maintain the body’s immune system. T cell is developed are thymus and are responsible for fighting against bacteria, viruses, and other infection-causing agents. The gland produces T cells until old age.

The growing prevalence of thymus cancer worldwide boosts the growth of the thymus cancer market. According to the American Society of Clinical Oncology (ASCO), 400 people develop thymoma every year. The tumors in thymus cancer are begun with thymoma. Additionally, rising research and development expenditure in the field of cancer treatment promotes the expansion of the thymus cancer market with the introduction of innovative drugs. As per the American Society of Clinical Oncology (ASCO), researchers are studying various new treatment methods for people with thymoma and thymic carcinoma. Several new drugs are studied in clinical trials including avelumab, amrubicin, buparlisib, belinostat, and saracatinib. In addition, the aged people are more prone to have thymus cancer. The rising geriatric population globally contributes to the expansion of the thymus cancer market. As per a report, “An Aging World: 2015”, around 17 percent of the World’s population is aged 65 and over by 2050. Further, the availability of effective treatment for thymus cancer led to the development of the thymus cancer market. On the flip side, the side effects of the treatment hinder the growth of the thymus cancer market. Moreover, new product launches for the treatment of thymus cancer create numerous opportunities for the growth of the thymus cancer market.

Geographically, the global thymus cancer market is divided into North America, Asia-Pacific., Europe, and the Rest of the World. North America is expected to have a dominant share in the global thymus cancer market. The growing allergic cases in the United States such as hereditary angioedema that in extreme cases result in thymus cancer led to the expansion of thymus cancer in the North American region. According to the American Society of Clinical Oncology (ASCO), less than 1 person per 1.5 million people has thymoma in the United States. Europe is anticipated to grow with a significant CAGR in the global thymus cancer market over the forecast period. Advanced medical facilities and growing research and development in cancer treatment in Europe drives the growth of the thymus cancer market in Europe. Asia-Pacific region is growing in the global thymus cancer market with a healthy CAGR over the forecast period. The growth of the market in the Asia-Pacific region is attributed to rising awareness about different types of cancer and a surge in demand for better medical facilities regarding the treatment of cancer in the region. 

Segment Covered

The report on global thymus cancer market covers segments such as cancer type, treatment type, and end-user. On the basis of cancer type, the sub-markets include thymic carcinoma, and thymoma. On the basis of treatment type, the sub-markets include surgery, chemotherapy, radiation therapy, and other treatment types. On the basis of end-user, the sub-markets include hospitals and clinics, research and academic institutes, and other end-users.

Companies Profiled:

The report provides profiles of the companies in the market such as Celegene Corporation, Eli Lilly and Company, Novartis International AG, Takeda Pharmaceutical Company Limited, Teva Pharmaceutical Industries Ltd., Tiziana Life Sciences plc, Amgen Inc., Merck and Co., Inc., Johnson & Johnson Services, Inc., Onxeo SA, and Other companies.

Report Highlights:

The report provides deep insights into the demand forecasts, market trends, and micro and macro indicators. In addition, this report provides insights into the factors that are driving and restraining the growth in this market. Moreover, The IGR-Growth Matrix analysis given in the report brings an insight into the investment areas that existing or new market players can consider. The report provides insights into the market using analytical tools such as Porter's five forces analysis and DRO analysis of thymus cancer market. Moreover, the study highlights current market trends and provides forecast from 2019-2025. We also have highlighted future trends in the market that will affect the demand during the forecast period. Moreover, the competitive analysis given in each regional market brings an insight into the market share of the leading players.